Table 2.

Literature search agents (17) reported to have no effect on the QTc interval in humans: concordance with animal QTc studies

Agent	Clinical use	↑QTc human	↑QTc animal	Referencesa
Alinidine	Negative chronotrope	−	−	(h): UW Wiegand et al., J Cardiovasc Pharmacol 4:59–62 (1982)
				(d): Traunecker W, Walland A, Arch Int Pharmacodyn Ther 244:58–72 (1980)
Almotriptan	Anti-migraine	−	−	(h): M Boyce et al., J Cardiovasc Pharmacol 37:280–289 (2001)
				(d): J Gras et al., Eur J Pharmacol 410:53–59 (2000)
Amlodipine	Anti-hypertensive	−	−	(h): K Porthan et al., Ann Med 41:29–37 (2009).
				(d): M Fujisawa et al., J Cardiovasc Pharmacol 53:325–32 (2009)
Amoxicillin	Antibiotic	−	−	(h): T Omata et al., J Pharmacol Sci 99:531–541 (2005)
				(d): S Toyoshima et al., J Pharmacol Sci 99:459–71 (2005)
Amrinone	Positive Inotrope	−	−	(h): GV Naccarelli et al., Am J Cardiol 54:600–4 (1984)
				(d): G Onuaguluchi et al., Arch Int Pharmacodyn Ther 264:263–73 (1983)
Aspirin	Analgesic	−	−	(h): AM Tonkin Aust N Z J Med 22:631–635 (1992).
				(d): LA Hanson et al., J Pharmacol Toxicol Meth 54:116–29 (2006)
				(r): LM Hondeghem & P Hoffman J Cardiovasc Pharmacol 41:14–24 (2003).
Captopril	Anti-hypertensive	−	−	(h): T Omata et al., J Pharmacol Sci 99:531–541 (2005)
				(d): S Toyoshima et al., J Pharmacol Sci 99:459–71 (2005)
Ceterizine	Antihistamine	−	−	(h): R Hulhoven et al., Eur J Clin Pharmacol 63:1011–1017 (2007).
				(d): J Weissenburger et al., Clin Exp Allergy 29(Suppl 3):190–196 (1999).
Cilnidipine	Anti-hypertensive	−	−	(h): N Ashizawa et al., International Society for Hypertension (ISH) – Hypertension Sydney Abstract 468 (2012).
				(d): A Takahara et al., Br J Pharmacol 158:1366–1374 (2009).
Ciprofloxacin	Antibiotic	−	−	(h): JP Tsikouris et al. Ann Noninvasive Electrocardiol 11:52–56 (2006).
				(d): S Toyoshima et al. J Pharmacol Sci 99:459–471 (2005)
Enalapril	Anti-hypertensive	−	−	(h): FJ Seara et al., Ann Noninvasive Electrocardiol 8:47–54 (2003)
				(g): P Hess et al., Lab Anim 41:470–80 (2007)
Enalaprilat	Anti-hypertensive	−	−	(h): H Bonnemeier et al., Pacing Clin Electrophysiol 30:631–7 (2007)
				(r): A Kijtawornrat et al., J Pharmacol Toxicol Methods 53:168–73 (2006)
Ibandronic acid	Osteoporosis	−	−	(h): BONIVA™ (ibandronate sodium) FDA Clinical Pharmacology & Biopharmaceutics Review (NDA 21–858), 2005
				(d): BONIVA™ (ibandronate sodium) FDA Clinical Pharmacology & Biopharmaceutics Review (NDA 21–858), 2005
Mefloquine	Anti-malarial	−	−	(h): M Bindschedler et al., Eur J Clin Pharmacol 56:375–81 (2000)
				(r): ID Lightbown et al., Br J Pharmacol 132:197–204 (2001)
Nifedipine	Anti-hypertensive	−	+	(h): L Alberio et al., Schweiz Med Wochenschr 122:1723–7 (1992)
				(d): S Toyoshima et al., J Pharmacol Sci 99:459–471 (2005)
Propranolol	Anti-hypertensive	−	−	(h): PE Puddu et al. Br Heart J 44:604–605 (1980).
				(d): LA Hanson et al., J Pharmacol Toxicol Meth 54:116–29 (2006)
Verapamil	Anti-hypertensive	−	+	(h): JL Holtzman et al., Clin Pharmacol Ther 46:26–32 (1989)
				(d): S Toyoshima et al., J Pharmacol Sci 99:459–471 (2005)

^aThe reference corresponds to a representative QTc study conducted in humans (h), primates (m), dogs (d), rabbits (r), guinea pigs (g).